Here, we demonstrate for the first time that ESR1 mutation is detrimental in primary breast cancer, showing that ESR1 ET resistance mutations that preexist any systemic therapy are associated to poor OS and RFS in patients who receive adjuvant ET. This evidence concerns the gene ESR1 and breast carcinoma.